GO:0004960 thromboxane receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004960 thromboxane receptor activity is defined as combining with a thromboxane (TXA) to initiate a change in cell activity.
• The thromboxane-prostanoid (TP) receptor is a G protein-coupled receptor that mediates vasoconstriction, platelet activation, and inflammation.
• Thromboxane receptor signaling drives persistent fibroblast activation in pulmonary fibrosis, making it a therapeutic target.
• Thromboxane receptor activation in dendritic cells mitigates sepsis by suppressing S100a8/a9-mediated neutrophil recruitment.
• Thromboxane receptor antagonists such as BMS 180,291 and ICI 180080 have shown antiplatelet activity in preclinical models.
• CRISPR knockout, point mutation, and knock-in models are essential for dissecting thromboxane receptor function in disease.
Description
Thromboxane receptor activity (GO:0004960) is a molecular function that mediates cellular responses to thromboxane A2 (TXA2) and related prostanoids. This activity is critical for vascular homeostasis, hemostasis, and inflammation, and its dysregulation contributes to thrombosis, pulmonary fibrosis, and sepsis. The receptor, often termed the thromboxane-prostanoid (TP) receptor, is a G protein-coupled receptor (GPCR) that couples to Gq/11 and G12/13 signaling pathways to initiate changes in cell activity. Researchers study this activity to understand cardiovascular disease mechanisms and to develop targeted therapies. Pharmacological tools such as thromboxane synthase inhibitors and receptor antagonists have been developed, but genetic models are needed to dissect causal roles. This article provides a research-grade overview of GO:0004960, including its mechanism, key genes, disease relevance, and CRISPR-based research methods.
thromboxane receptor activity At A Glance
| GO ID | GO:0004960 |
|---|---|
| GO term | thromboxane receptor activity |
| Ontology | molecular_function |
| Synonym | TXA receptor activity |
| Major function | Binding of thromboxane to initiate intracellular signaling and cellular responses |
| Receptor family | G protein-coupled receptor (GPCR) |
| Endogenous ligands | Thromboxane A2 (TXA2) and related prostanoids |
| Major signaling pathways | Gq/11-mediated calcium mobilization and G12/13-mediated Rho activation |
| Physiological roles | Vasoconstriction, platelet aggregation, inflammation, and hemostasis |
What Is GO:0004960?
Thromboxane receptor activity (GO:0004960) is the molecular function of combining with a thromboxane molecule, such as thromboxane A2, to initiate a change in cell activity. This activity is mediated by the thromboxane-prostanoid (TP) receptor, a G protein-coupled receptor that transduces signals from thromboxane and related prostanoids.
Why Is thromboxane receptor activity Important in Cell Biology?
Thromboxane receptor activity is a central mediator of cardiovascular and inflammatory processes, and its pharmacological modulation has been a therapeutic strategy for thrombotic disorders. Understanding this activity at the molecular level is essential for developing safer and more effective drugs targeting the TP receptor.
• Mediates platelet activation and aggregation, contributing to thrombosis.
• Regulates vascular tone and blood pressure through vasoconstriction.
• Plays a role in pulmonary fibrosis by driving persistent fibroblast activation.
• Modulates immune responses in sepsis by affecting dendritic cell function.
• Is a target for antiplatelet drugs such as thromboxane receptor antagonists.
• Involved in oxidative stress and inflammation in cardiovascular disease.
• Losartan, an angiotensin receptor blocker, suppresses platelet activity by interfering with thromboxane signaling.
• Genetic variations in the receptor may affect drug responses and disease susceptibility.
• Provides a model for studying GPCR pharmacology and signaling.
• CRISPR-based editing enables precise functional studies of the receptor in disease models.
Molecular Mechanism of thromboxane receptor activity
Ligand Binding and Receptor Activation
In simple terms: Thromboxane binds to the receptor like a key in a lock, turning it on.
Thromboxane A2 (TXA2) is the primary endogenous ligand for the thromboxane receptor (TP receptor). Upon binding, the receptor undergoes conformational changes that enable coupling to heterotrimeric G proteins. This binding is highly specific and initiates a cascade of intracellular events.
G Protein Coupling and Second Messenger Generation
In simple terms: The activated receptor talks to G proteins, which then send signals inside the cell.
The TP receptor primarily couples to Gq/11, activating phospholipase C (PLC) to produce inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to calcium mobilization and protein kinase C (PKC) activation. It also couples to G12/13, activating Rho kinase pathways.
Downstream Signaling and Cellular Responses
In simple terms: The signals cause the cell to change its behavior, like contracting or releasing factors.
Downstream effects include platelet shape change, aggregation, and granule release; vascular smooth muscle contraction; and fibroblast proliferation and extracellular matrix production. In dendritic cells, TP receptor activation suppresses S100a8/a9-mediated neutrophil recruitment, mitigating sepsis.
Regulation and Desensitization
In simple terms: The receptor can be turned off or tuned down after activation.
Receptor desensitization involves phosphorylation by G protein-coupled receptor kinases (GRKs) and arrestin recruitment, leading to internalization. Chronic activation can lead to receptor upregulation or altered signaling, contributing to disease states such as pulmonary fibrosis.
Key Genes Involved in GO:0004960 thromboxane receptor activity
The following genes and proteins are key components of thromboxane receptor activity and its signaling network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TBXA2R | Encodes the thromboxane A2 receptor (TP receptor) | Primary receptor for thromboxane; target for knockout and point mutation studies |
| TBXAS1 | Thromboxane A synthase 1, synthesizes TXA2 | Enzyme upstream of receptor activation; target for inhibitors |
| GNAQ | Gq alpha subunit, couples to TP receptor | Mediates calcium signaling; knockout affects receptor function |
| GNA12 | G12 alpha subunit, couples to TP receptor | Activates Rho pathway; involved in vascular tone |
| PTGS1 | Cyclooxygenase-1, produces prostaglandin H2 | Upstream of thromboxane synthesis; target of aspirin |
| PTGS2 | Cyclooxygenase-2, inducible isoform | Involved in inflammation; modulates thromboxane production |
| PLCB1 | Phospholipase C beta 1 | Downstream effector of Gq signaling |
| RHOA | RhoA GTPase | Mediates G12/13 signaling; regulates cytoskeleton |
| ROCK1 | Rho-associated kinase 1 | Downstream of RhoA; involved in contraction |
| MAPK1 | Mitogen-activated protein kinase 1 | Modulates gene expression downstream of TP receptor |
| S100A8 | S100 calcium-binding protein A8 | Suppressed by TP receptor activation in dendritic cells |
| S100A9 | S100 calcium-binding protein A9 | Suppressed by TP receptor activation in dendritic cells |
| ITGA2B | Integrin alpha 2b (platelet glycoprotein IIb) | Mediates platelet aggregation downstream of TP receptor |
| ITGB3 | Integrin beta 3 (platelet glycoprotein IIIa) | Forms complex with ITGA2B; platelet aggregation |
| VEGFA | Vascular endothelial growth factor A | Induced by TP receptor activation in fibrosis |
| COL1A1 | Collagen type I alpha 1 chain | Upregulated in fibrosis downstream of TP receptor |
| ACTA2 | Actin alpha 2, smooth muscle | Marker of myofibroblast activation in fibrosis |
| IL6 | Interleukin 6 | Inflammatory cytokine modulated by TP receptor |
How Is thromboxane receptor activity Regulated?
Thromboxane receptor activity is regulated at multiple levels. Receptor expression can be modulated by inflammatory cytokines and growth factors. Desensitization and internalization are controlled by GRK-mediated phosphorylation and arrestin binding. In pulmonary fibrosis, persistent fibroblast activation is driven by sustained TP receptor signaling, suggesting dysregulated regulation. Additionally, angiotensin receptor blockers like losartan can interfere with thromboxane signaling, indicating crosstalk with the renin-angiotensin system.
thromboxane receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TBXA2R | Thrombosis, cardiovascular disease | Platelet-specific knockout or point mutation in mice |
| TBXA2R | Pulmonary fibrosis | Fibroblast-specific knockout or overexpression in bleomycin model |
| TBXA2R | Sepsis | Dendritic cell-specific knockout in LPS-induced sepsis model |
| TBXAS1 | Thrombotic disorders | Thromboxane synthase inhibitor treatment in animal models |
| PTGS1 | Platelet activation | Aspirin treatment or knockout in platelets |
Thromboxane Receptor in Cardiovascular Disease
Thromboxane receptor activity is critically involved in thrombosis and hemostasis. TP receptor antagonists have been developed as antiplatelet agents for thrombotic disorders. In monkeys, the long-acting thromboxane receptor antagonist BMS 180,291 demonstrated antiplatelet activity. Losartan, an angiotensin receptor blocker, suppresses platelet activity by interfering with thromboxane signaling, highlighting crosstalk between systems.
Thromboxane Receptor in Pulmonary Fibrosis
Thromboxane-prostanoid receptor signaling drives persistent fibroblast activation in pulmonary fibrosis. This suggests that TP receptor antagonists may have therapeutic potential in fibrotic diseases by attenuating myofibroblast activation and collagen deposition.
Thromboxane Receptor in Sepsis and Inflammation
Thromboxane receptor activation in dendritic cells mitigates sepsis by suppressing S100a8/a9-mediated neutrophil recruitment. This identifies a protective role for TP receptor signaling in sepsis, contrasting with its pro-inflammatory effects in other contexts.
From thromboxane receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TBXA2R knockout affect platelet aggregation? | Platelet-specific TBXA2R knockout mouse |
| Does a point mutation in TBXA2R alter ligand binding? | CRISPR knock-in of point mutation in cell lines |
| Does TBXA2R overexpression drive fibrosis? | Fibroblast-specific overexpression in mouse lung |
| Does TBXA2R activation in dendritic cells protect against sepsis? | Dendritic cell-specific knockout or agonist treatment |
| Can TP receptor antagonists inhibit thrombosis? | Animal models of thrombosis treated with antagonists |
| Does losartan interfere with thromboxane signaling? | Platelet function assays in patients or animal models |
How to Study the thromboxane receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Receptor-ligand affinity | Screening for receptor antagonists |
| Platelet aggregation assay | Platelet activation | Testing antiplatelet drugs |
| Calcium mobilization assay | Gq signaling | Assessing receptor activation |
| CRISPR knockout | Gene function loss | Validating receptor role in disease |
| RNA-seq | Transcriptomic changes | Identifying downstream targets |
| Proteomics | Protein expression changes | Discovering biomarkers |
| Immunohistochemistry | Protein localization | Assessing receptor expression in tissues |
| Animal disease models | In vivo efficacy | Testing therapeutic interventions |
Pharmacological and Biochemical Assays
Thromboxane receptor activity can be measured using radioligand binding assays with labeled thromboxane analogs, and functional assays such as platelet aggregation and calcium mobilization. These methods are used to screen for receptor antagonists.
Genetic Knockout and Knock-in Models
CRISPR/Cas9-mediated knockout of TBXA2R in cell lines or animal models allows assessment of receptor function in disease. Knock-in of point mutations can model human polymorphisms and assess their impact on signaling.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can identify downstream targets of TP receptor signaling, such as S100a8/a9 in dendritic cells and collagen in fibroblasts. These approaches reveal molecular mechanisms of disease.
In Vivo Disease Models
Animal models of thrombosis, pulmonary fibrosis, and sepsis are used to test the effects of TP receptor modulation. These models are essential for translational research.
How CRISPR Can Be Used to Study GO:0004960 thromboxane receptor activity
Knockout
CRISPR knockout of TBXA2R in cell lines or animal models is used to study loss of thromboxane receptor activity. For example, dendritic cell-specific knockout revealed a protective role in sepsis. Fibroblast knockout attenuated pulmonary fibrosis in mice.
Point Mutation
Point mutations in TBXA2R can be introduced using CRISPR base editing or homology-directed repair to model human polymorphisms. These models help assess the impact of specific amino acid changes on receptor signaling and drug response.
Knock-in
Knock-in of reporter genes or epitope tags into the TBXA2R locus allows visualization and purification of the receptor. This is useful for studying receptor trafficking and interactions.
Overexpression
Overexpression of TBXA2R in cell lines or transgenic animals can model receptor gain-of-function and its contribution to diseases such as fibrosis. This approach is valuable for drug screening.
How EDITGENE Supports thromboxane receptor activity Research
Researchers studying thromboxane receptor activity-related genes often need to determine whether a candidate gene is causally involved in disease or whether its modulation can alter cellular phenotypes. EDITGENE provides CRISPR-based services to enable precise genetic editing for such studies.
Contact EDITGENE today to design your custom CRISPR model for thromboxane receptor activity research.
Frequently Asked Questions About thromboxane receptor activity
What is thromboxane receptor activity?
Thromboxane receptor activity (GO:0004960) is the molecular function of binding thromboxane to initiate a change in cell activity, primarily mediated by the TP receptor.
What genes are involved in thromboxane receptor activity?
Key genes include TBXA2R (the receptor), TBXAS1 (synthase), and downstream signaling genes like GNAQ and RHOA.
What diseases are associated with thromboxane receptor activity?
Thrombosis, pulmonary fibrosis, and sepsis are associated with altered thromboxane receptor signaling.
How is thromboxane receptor activity studied?
It is studied using pharmacological assays, CRISPR knockout models, and animal disease models.
What is the role of TBXA2R in platelets?
TBXA2R mediates platelet activation and aggregation, making it a target for antiplatelet drugs.
Can thromboxane receptor antagonists treat thrombosis?
Yes, antagonists such as BMS 180,291 have shown antiplatelet activity in preclinical models.
What is the link between thromboxane receptor and pulmonary fibrosis?
TP receptor signaling drives persistent fibroblast activation, contributing to fibrosis.
How does thromboxane receptor activation affect sepsis?
In dendritic cells, TP receptor activation suppresses S100a8/a9-mediated neutrophil recruitment, mitigating sepsis.
What CRISPR models are available for thromboxane receptor research?
Knockout, point mutation, knock-in, and overexpression models can be generated for TBXA2R and related genes.
Does losartan affect thromboxane signaling?
Losartan suppresses platelet activity by interfering with thromboxane signaling.
Conclusion
Thromboxane receptor activity (GO:0004960) is a critical molecular function in cardiovascular and inflammatory diseases. Its modulation by pharmacological agents and genetic editing offers therapeutic potential. CRISPR-based models are invaluable for dissecting its role in disease and for drug discovery.
References
- 1. Du R et al.. 2026. Thromboxane receptor activation in dendritic cells mitigates sepsis by suppressing S100a8/a9-mediated neutrophil recruitment.. Signal Transduct Target Ther 11(1) PMID: 41771826
- 2. Félétou M et al.. 2010. Vasoconstrictor prostanoids.. Pflugers Arch 459(6):941-50 PMID: 20333529
- 3. Suzuki T et al.. 2022. Thromboxane-Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis.. Am J Respir Crit Care Med 206(5):596-607 PMID: 35728047
- 4. Schwemmer M et al.. 2001. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.. Cardiovasc Drugs Ther 15(4):301-7 PMID: 11800413
- 5. Capra V et al.. 2014. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.. J Thromb Haemost 12(2):126-37 PMID: 24298905
- 6. Gresele P et al.. 1991. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.. Trends Pharmacol Sci 12(4):158-63 PMID: 1829559
- 7. Schumacher WA et al.. 1992. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys.. Prostaglandins 44(5):389-97 PMID: 1301074
- 8. Brown GR et al.. 1986. ICI 180080, a novel selective thromboxane receptor antagonist: synthesis and relative activity.. J Pharm Pharmacol 38(9):706-8 PMID: 2877076
